Georgia Medicare Lung Cancer Screening LDCT 2026 Guide

Medicare covers annual lung cancer screening with low-dose computed tomography (LDCT) for eligible beneficiaries through National Coverage Determination (NCD) 210.14, established under the Section 1861(ddd) preventive services authority. CMS has expanded the eligibility criteria over time, lowering the age threshold from 55 to 50 and reducing the smoking history pack-year threshold from 30 to 20, aligning coverage with updated U.S. Preventive Services Task Force (USPSTF) recommendations.

For Georgia Medicare beneficiaries, lung cancer screening is one of the most consequential preventive services available. Lung cancer is the leading cause of cancer death in Georgia and the United States. Georgia's smoking prevalence exceeds the national average, and rural Georgia counties, particularly in south, southwest, and southeast Georgia, face elevated smoking rates and lung cancer mortality. Lung cancer screening is notably different from other Medicare cancer screening benefits because it requires a counseling and shared decision-making visit (CSDM) before initial screening, requires radiology facility participation in a designated lung cancer screening registry, and uses Lung-RADS standardized reporting to coordinate management of incidental findings. This guide covers the statutory framework, eligibility, the CSDM requirement, LDCT requirements, HCPCS coding, cost-sharing under the ACA Section 4104 waiver, Lung-RADS coordination, tobacco cessation coordination, and the Georgia lung cancer screening landscape.

By Brevy Care Team

Part 1: The Statutory and Regulatory Framework

Section 1861(ddd) Preventive Services Authority

Section 1861(ddd) of the Social Security Act provides the statutory authority for CMS to add Medicare coverage for "additional preventive services" beyond those specifically enumerated in other parts of Section 1861. The authority requires that the additional preventive service:

• Is reasonable and necessary for the prevention or early detection of illness or disability.
• Is recommended with a grade of A or B by the USPSTF.
• Is appropriate for individuals entitled to benefits under Part A or enrolled under Part B.

This authority is the legal basis under which lung cancer screening was added to Medicare coverage following the 2013 USPSTF Grade B recommendation. Similar Section 1861(ddd) authority underlies coverage decisions for hepatitis C screening, depression screening, alcohol misuse counseling, and other USPSTF-aligned preventive services.

National Coverage Determination 210.14

CMS issued National Coverage Determination 210.14 to add Medicare coverage for lung cancer screening with low-dose computed tomography. The original NCD specified:

• Age 55 to 77 eligibility.
• 30 pack-year cumulative smoking history.
• Current smoker or quit within past 15 years.
• Asymptomatic for lung cancer.
• Required counseling and shared decision-making visit before initial screening.
• LDCT screening annually.
• Radiology facility designated registry participation requirement.

NCD 210.14 was informed by National Lung Screening Trial evidence demonstrating that LDCT screening reduces lung cancer mortality in high-risk smokers compared to chest X-ray screening.

NCD 210.14 Eligibility Expansion

CMS issued a revised NCD 210.14 to expand the eligibility criteria. The expansion lowered:

• Age threshold: from 55 to 50.
• Pack-year threshold: from 30 to 20.

The other criteria (current smoker or quit within past 15 years, asymptomatic, CSDM, designated registry participation) remained the same. The age 77 upper limit was retained.

The expansion aligned Medicare coverage with updated USPSTF recommendations reflecting accumulated evidence that screening benefits extend to lower-risk individuals and that earlier and broader screening reduces lung cancer mortality. The expansion was particularly relevant for racial and ethnic minorities and women who had been disproportionately excluded under the more restrictive prior criteria.

USPSTF Recommendation History

The USPSTF lung cancer screening recommendation has evolved with accumulating evidence. The current USPSTF Grade B recommendation supports LDCT screening for adults age 50-80 with a 20 pack-year smoking history who are current smokers or have quit within 15 years. NCD 210.14 aligns with this recommendation, with the upper age limit set at 77 rather than 80, reflecting CMS judgment about the age range where screening benefits clearly outweigh harms in the Medicare population.

Related Statutory and Regulatory Authority

Several other Medicare provisions coordinate with the lung cancer screening benefit:

• Section 1861(ww) SSA — Initial Preventive Physical Examination (IPPE, Welcome to Medicare visit).
• Section 1861(hhh) SSA — Annual Wellness Visit (AWV).
• Section 1861(s)(2)(EE) SSA — Tobacco cessation counseling.
• ACA Section 4104 — Preventive services cost-sharing waiver for USPSTF Grade A or B aligned services.

Part 2: Eligibility Criteria

Age Eligibility

Beneficiaries age 50 to 77 are eligible for Medicare-covered LDCT lung cancer screening. The age 50 lower limit reflects the 2022 expansion (down from age 55 originally). The age 77 upper limit reflects CMS judgment that beneficiaries older than 77 do not clearly benefit from screening because of competing risks from comorbidities, treatment intolerance, and limited life expectancy.

Smoking History

Beneficiaries must have a cumulative 20 pack-year smoking history. A "pack-year" is calculated as packs per day multiplied by years of smoking:

• 1 pack per day for 20 years = 20 pack-years.
• 2 packs per day for 10 years = 20 pack-years.
• 0.5 packs per day for 40 years = 20 pack-years.
• 1.5 packs per day for 14 years = 21 pack-years (eligible).

The 20 pack-year threshold reflects the 2022 expansion (down from 30 pack-years originally).

Current Smoker or Quit Within Past 15 Years

Beneficiaries must be current smokers or former smokers who quit within the past 15 years. Beneficiaries who quit smoking more than 15 years ago are not eligible for Medicare-covered LDCT screening, reflecting the diminishing residual lung cancer risk over time after smoking cessation.

Asymptomatic Status

Beneficiaries must be asymptomatic for lung cancer. Beneficiaries with symptoms (persistent cough, hemoptysis, weight loss, dyspnea, chest pain) require diagnostic CT, not screening LDCT. Diagnostic CT is billed under different CPT codes and is subject to standard Part B cost-sharing rather than the ACA Section 4104 waiver.

Counseling and Shared Decision-Making Visit (Before Initial Screening)

Before the initial LDCT screening, the beneficiary must have a counseling and shared decision-making visit (CSDM) with their physician or qualified non-physician practitioner. The CSDM is a billable visit under HCPCS G0296 and includes:

• Determination of eligibility (age, smoking history, asymptomatic status).
• Shared decision-making discussion of screening benefits and harms.
• Counseling on the importance of adherence to annual screening if eligible.
• Counseling on follow-up of incidental findings.
• Counseling on the importance of abstinence from smoking and tobacco cessation resources.
• Provision of written or verbal information.

The CSDM requirement is unique among Medicare preventive services and reflects the complexity of lung cancer screening (including potential harms of false-positive findings, incidental findings, and procedural complications from biopsy of suspicious lesions).

Annual Screening Frequency

Eligible beneficiaries qualify for annual LDCT screening. The annual frequency reset is calculated similarly to other annual preventive services — typically requiring 11 full months elapsed from the most recent screening before the next is covered.

Part 3: The Counseling and Shared Decision-Making Visit (CSDM)

CSDM Required Elements

The CSDM under HCPCS G0296 must include specific elements:

1. Eligibility determination: Verify age, smoking history (pack-years), and asymptomatic status against current NCD 210.14 criteria.

2. Shared decision-making: Discuss the potential benefits and harms of LDCT screening including:

   • Benefits: Lung cancer mortality reduction, earlier-stage detection allowing curative treatment.
   • Harms: False-positive findings leading to invasive workup, overdiagnosis, radiation exposure, anxiety, complications of biopsy of suspicious lesions.

3. Adherence counseling: Explain the importance of adherence to annual screening for ongoing benefit.

4. Incidental findings counseling: Explain that LDCT screening may identify incidental findings (lung nodules of indeterminate significance, mediastinal nodes, thyroid abnormalities, adrenal abnormalities, cardiac calcifications, emphysema) requiring follow-up.

5. Tobacco cessation counseling: Strongly recommend cessation for current smokers; reinforce abstinence for former smokers; provide cessation resources.

6. Documentation: The CSDM must be documented in the medical record with the elements above.

CSDM Provider Requirements

The CSDM must be performed by a physician or qualified non-physician practitioner. Acceptable providers include:

• Physicians (MDs and DOs).
• Nurse practitioners (within scope of practice).
• Physician assistants (within scope of practice).
• Clinical nurse specialists (within scope of practice).

CSDM Frequency

The CSDM is required before the initial LDCT screening. Subsequent annual screenings do not require a new CSDM, though clinical practice often includes annual reinforcement of cessation and adherence counseling within the AWV or routine primary care.

CSDM Cost-Sharing

The CSDM under HCPCS G0296 is subject to the ACA Section 4104 cost-sharing waiver. Beneficiaries pay $0 for the CSDM when it is performed in advance of eligible LDCT screening.

Part 4: LDCT Technical Requirements

LDCT Protocol

Low-dose CT for lung cancer screening uses a specialized low-radiation-dose protocol that delivers substantially less radiation than a standard diagnostic chest CT.

The LDCT protocol uses:

• Helical CT acquisition through the chest.
• Specific tube current and voltage parameters optimized for low dose.
• Multiplanar reconstruction allowing axial, coronal, and sagittal review.
• Lung-window image review.

The radiologist interprets the LDCT and reports findings using the Lung-RADS reporting system.

Facility Requirements

Radiology facilities performing Medicare-covered LDCT lung cancer screening must:

• Be enrolled with Medicare as a Part B provider.
• Use a qualified LDCT screening protocol.
• Participate in a CMS-designated lung cancer screening registry (typically the American College of Radiology Lung Cancer Screening Registry).
• Maintain quality assurance and patient outcome tracking through registry reporting.

The registry participation requirement is unique among Medicare cancer screening benefits and supports ongoing quality monitoring and outcome research.

LDCT Billing Code

LDCT lung cancer screening is billed under HCPCS G0297. The code is specific to lung cancer screening LDCT and is distinct from diagnostic CT codes (CPT 71250, 71260, 71270).

LDCT Frequency Calculation

Annual LDCT screening requires that the prior screening was performed at least 11 full months before the next screening. For example, if the beneficiary had screening LDCT on March 10, 2026, the next screening is covered on or after February 1, 2027.

Part 5: Lung-RADS Reporting and Management

Lung-RADS Overview

The Lung Imaging Reporting and Data System (Lung-RADS) is the standardized reporting system developed by the American College of Radiology for communicating LDCT findings. Lung-RADS categorizes findings from 1 (negative, no nodules) through 4X (highly suspicious for malignancy) and specifies management pathways for each category.

Lung-RADS Categories and Management

Cost-Sharing for Lung-RADS Follow-Up

When LDCT screening identifies abnormal findings requiring follow-up imaging or diagnostic workup, the follow-up services are NOT subject to the ACA Section 4104 cost-sharing waiver. Follow-up services are subject to standard Part B cost-sharing:

• Follow-up CT (Lung-RADS 3 or 4): Standard Part B cost-sharing.
• PET-CT: Standard Part B cost-sharing.
• Biopsy (CT-guided, bronchoscopic, surgical): Standard Part B cost-sharing.
• Specialist consultation (pulmonology, thoracic surgery): Standard Part B cost-sharing.

This screening-to-diagnostic cost-sharing distinction can produce unexpected follow-up costs for beneficiaries identified with abnormal findings.

Incidental Findings

LDCT screening commonly identifies incidental findings outside the primary lung nodule focus. Common incidental findings include:

• Coronary artery calcifications (CAC) suggesting cardiovascular disease.
• Aortic abnormalities.
• Mediastinal lymphadenopathy.
• Thyroid nodules.
• Adrenal abnormalities.
• Liver abnormalities (visible at the upper abdomen).
• Emphysema and other parenchymal lung disease.

Incidental findings require appropriate clinical follow-up depending on significance, and any subsequent imaging or workup is subject to standard Part B cost-sharing.

Part 6: Tobacco Cessation Coordination

Medicare Tobacco Cessation Counseling Benefit

Section 1861(s)(2)(EE) of the Social Security Act provides Medicare coverage for tobacco cessation counseling under HCPCS G0436 (intermediate cessation counseling, 3-10 minutes) and G0437 (intensive cessation counseling, more than 10 minutes). Coverage applies regardless of symptoms, supporting multiple cessation counseling sessions per year.

Tobacco cessation counseling is subject to the ACA Section 4104 cost-sharing waiver. Beneficiaries pay $0 for cessation counseling.

Integration With Lung Cancer Screening Workflow

The CSDM workflow explicitly requires counseling on the importance of abstinence from smoking. Many lung cancer screening programs integrate tobacco cessation services into the screening workflow:

• CSDM identifies current smokers and provides cessation counseling.
• Cessation counseling referrals to dedicated programs.
• Pharmacotherapy support (nicotine replacement therapy, varenicline, bupropion).
• Annual LDCT screening visits provide ongoing cessation reinforcement.

Georgia Tobacco Quit Line

The Georgia Tobacco Quit Line (1-877-270-7867) provides free cessation counseling and resources to Georgia residents, including coaching support, cessation planning, and pharmacotherapy referrals. Lung cancer screening programs commonly refer current smokers to the Quit Line as part of the CSDM and ongoing screening workflow.

Cessation Pharmacotherapy

Medicare Part D plans typically cover cessation pharmacotherapy:

• Nicotine replacement therapy (gums, lozenges, patches, sprays).
• Varenicline (Chantix).
• Bupropion sustained-release (Zyban).

Coverage details and formulary placement vary by plan; beneficiaries should check their plan formulary or call their plan for specifics.

Part 7: Cost-Sharing Structure

ACA Section 4104 Cost-Sharing Waiver

Section 4104 of the Affordable Care Act eliminated Part B deductible and coinsurance for USPSTF Grade A or B aligned preventive services. The USPSTF grades lung cancer screening Grade B, qualifying it for the ACA Section 4104 cost-sharing waiver.

The waiver applies to:

• The counseling and shared decision-making visit (HCPCS G0296).
• The LDCT screening (HCPCS G0297).

For these services, Medicare beneficiaries pay $0.

Standard Part B Cost-Sharing for Diagnostic Follow-Up

Diagnostic follow-up of LDCT findings is NOT subject to the ACA Section 4104 waiver. Standard Part B cost-sharing applies (Part B deductible plus 20 percent coinsurance) for:

• Follow-up CT for Lung-RADS 3 (probably benign, 6-month follow-up).
• Follow-up CT for Lung-RADS 4 (suspicious, 3-month follow-up).
• PET-CT.
• CT-guided biopsy or bronchoscopic biopsy.
• Surgical biopsy or resection.
• Specialist consultation (pulmonology, thoracic surgery, oncology).
• Workup of incidental findings.

This screening-to-diagnostic cost-sharing distinction can produce unexpected costs for beneficiaries who are screened and identified with findings requiring follow-up. Pre-screening counseling at the CSDM addresses this expectation.

Cost-Sharing Summary Table

Part 8: Coordination With Other Medicare Preventive Services

Coordination With the Annual Wellness Visit

The Annual Wellness Visit (AWV), authorized by Section 1861(hhh) of the Social Security Act, includes a personalized prevention plan that documents preventive services status and recommendations. Lung cancer screening is a routine AWV component for eligible beneficiaries:

• Smoking history documentation including pack-year calculation.
• Eligibility assessment for LDCT screening per NCD 210.14 criteria.
• CSDM scheduling for newly eligible beneficiaries.
• Annual screening adherence support for previously screened beneficiaries.
• Tobacco cessation counseling for current smokers.

Coordination With the Initial Preventive Physical Examination

The Initial Preventive Physical Examination (IPPE) authorized by Section 1861(ww) is the one-time preventive visit available within the first 12 months of Part B enrollment. The IPPE includes assessment of preventive services needs and identification of LDCT screening eligibility for beneficiaries with appropriate smoking history.

Coordination With Other Cancer Screening

Many Medicare beneficiaries receive coordinated cancer screening — lung cancer (LDCT), colorectal cancer, breast cancer (women), prostate cancer (men), and cervical cancer (women) — through the same primary care visit cycle. The AWV serves as the natural coordinating visit.

Part 9: The Major Georgia Lung Cancer Screening Landscape

Atlanta Metropolitan Area

The Atlanta metropolitan area has extensive lung cancer screening capacity:

• Emory Lung Cancer Screening Program — Academic LDCT screening at Emory University with integrated thoracic oncology, pulmonology, thoracic surgery, and tobacco cessation services.
• Wellstar Lung Cancer Screening — Network-wide LDCT screening across the north and west Atlanta metropolitan area.
• Piedmont Lung Cancer Screening — Piedmont Healthcare LDCT screening with multiple locations.
• Northside Hospital Lung Cancer Screening — Strong lung cancer screening presence in north Atlanta.
• Grady Health System Lung Cancer Screening — Safety-net lung cancer screening serving central Atlanta.

Augusta and East Georgia

Augusta University Lung Cancer Screening serves east Georgia with academic LDCT screening through the Georgia Cancer Center.

Macon and Central Georgia

Atrium Health Navicent (Macon) and Coliseum Medical Centers provide LDCT screening for central Georgia.

Savannah and Coastal Georgia

Memorial Health (Savannah) and St. Joseph's Candler Health System provide LDCT screening for coastal Georgia.

Albany and Southwest Georgia

Phoebe Putney Memorial Hospital (Albany) provides LDCT screening for southwest Georgia.

Athens and Northeast Georgia

Piedmont Athens Regional and St. Mary's Health Care System provide LDCT screening for the Athens area and northeast Georgia.

ACR Lung Cancer Screening Registry Participation

All Medicare-eligible LDCT screening facilities must participate in a CMS-designated lung cancer screening registry. The American College of Radiology Lung Cancer Screening Registry (LCSR) is the dominant registry. Beneficiaries and clinicians can verify facility registry participation through the ACR's facility locator.

Rural Georgia Access

Many rural Georgia counties lack local LDCT screening facilities. Beneficiaries in counties without local screening typically travel to regional medical centers for the CSDM (sometimes provided by primary care, sometimes coordinated with the screening facility) and the LDCT itself. Some rural primary care practices coordinate referral pathways to regional screening centers (Albany, Macon, Augusta, Savannah, Athens, Atlanta).

Part 10: Lung Cancer Disease Burden in Georgia

Lung Cancer as Leading Cause of Cancer Death

Lung cancer is the leading cause of cancer death in Georgia and in the United States. The Georgia Comprehensive Cancer Registry tracks state-level lung cancer incidence and mortality, consistently documenting elevated burden particularly in rural counties of south, southwest, and southeast Georgia.

Smoking Prevalence in Georgia

Georgia's adult smoking prevalence has historically exceeded the national average. Rural Georgia counties show particularly elevated smoking rates, contributing to elevated lung cancer mortality. Public health initiatives including the Georgia Tobacco Use Prevention Program work to reduce smoking initiation and support cessation.

Stage at Diagnosis

Without screening, most lung cancers present at advanced stage when curative treatment is no longer possible. LDCT screening shifts the stage distribution toward earlier stages with substantially improved survival outcomes.

Rural Mortality Disparities

Rural Georgia counties face elevated lung cancer mortality reflecting:

• Higher smoking prevalence.
• Lower screening uptake.
• Geographic barriers to specialty care.
• Lower socioeconomic status correlating with health behaviors and access.

Racial Disparities

Black Americans face elevated lung cancer mortality despite similar incidence to non-Hispanic whites. This disparity reflects later-stage diagnosis at presentation, treatment access issues, and persistent socioeconomic factors. The 2022 NCD 210.14 expansion lowering eligibility thresholds was particularly important for racial minorities, who had been disproportionately excluded under the more restrictive 2015 criteria.

Part 11: Worked Examples

Worked Example 1: Atlanta Age 65 Current Smoker 25 Pack-Years CSDM and LDCT

Beneficiary: 65-year-old man in Fulton County, current smoker (1 pack per day for 25 years = 25 pack-years), no symptoms of lung cancer.

Eligibility: He is eligible — age 50-77 (65), smoking history 20+ pack-years (25), current smoker, asymptomatic.

He receives his AWV at his primary care physician at Emory. The physician documents the smoking history, calculates pack-years, and confirms eligibility. The physician performs the CSDM (G0296) including shared decision-making discussion, cessation counseling, and Quit Line referral.

The beneficiary schedules his first LDCT at Emory Lung Cancer Screening Program. LDCT is performed (G0297). Result: Lung-RADS 1 (negative). Recommended management: continue annual screening.

Billing: G0296 and G0297 subject to ACA Section 4104 waiver — $0 to beneficiary. He is scheduled for next annual LDCT in 12 months.

Worked Example 2: Rural Georgia Age 70 Former Smoker Quit 10 Years Ago

Beneficiary: 70-year-old woman in Worth County, smoked 1 pack per day for 30 years, quit 10 years ago.

Eligibility: She is eligible — age 50-77 (70), smoking history 20+ pack-years (30), quit within past 15 years (10 years ago), asymptomatic.

Her primary care physician at the Worth County FQHC performs the CSDM (G0296). The CSDM reinforces continued abstinence and discusses screening adherence. She is referred to Phoebe Putney for LDCT.

LDCT at Phoebe Putney (G0297). Result: Lung-RADS 2 (benign-appearing nodule, less than 6 mm). Recommended management: continue annual screening.

Billing: G0296 and G0297 under ACA waiver — $0. Annual LDCT scheduled.

Worked Example 3: Lung-RADS 4A Finding Referral to Thoracic Surgery

Beneficiary: 68-year-old in Cobb County, current smoker (40 pack-years), undergoes annual LDCT at Wellstar Lung Cancer Screening.

LDCT result: Lung-RADS 4A (suspicious solid nodule, 11 mm in the right upper lobe). Recommended management: 3-month follow-up LDCT, PET-CT, or biopsy.

The pulmonologist at Wellstar coordinates PET-CT showing FDG-avid uptake in the nodule (SUV 8.5) consistent with malignancy. CT-guided biopsy is performed showing non-small cell lung cancer adenocarcinoma.

Multidisciplinary thoracic oncology evaluation results in stage I treatment plan with curative-intent surgical resection (lobectomy).

Billing: Original LDCT (G0297) under ACA waiver — $0. PET-CT, biopsy, surgery, and all subsequent care subject to standard Part B cost-sharing.

This case illustrates the value of LDCT — without screening, this stage I lung cancer would likely have been diagnosed at much later stage when curative treatment is unavailable.

Worked Example 4: Age 55 Newly Eligible Per 2022 Expansion

Beneficiary: 55-year-old woman in Bibb County, smoked 1 pack per day for 22 years (22 pack-years), current smoker, no symptoms. She is enrolled in Medicare through SSDI eligibility.

Under the original 2015 NCD criteria (age 55-77, 30 pack-years), she would have been ineligible (pack-year history below 30). Under the 2022 expanded criteria (age 50-77, 20 pack-years), she is eligible.

Her primary care physician at Atrium Health Navicent performs the CSDM (G0296) and schedules her first LDCT at the Navicent lung cancer screening center.

LDCT (G0297). Result: Lung-RADS 1 (negative).

Billing: Under ACA waiver — $0.

This case illustrates the practical impact of the 2022 expansion — beneficiaries who would have been ineligible under the original 2015 criteria are now appropriately screened.

Worked Example 5: Counseling and Shared Decision-Making Refusal of Screening

Beneficiary: 72-year-old man in DeKalb County, current smoker (45 pack-years), no symptoms. He has significant COPD, congestive heart failure, and CKD stage 4 with estimated life expectancy less than 5 years.

His primary care physician at Emory performs the CSDM. The shared decision-making discussion addresses the harm-benefit balance given his comorbidities and limited life expectancy. The physician notes that screening could identify findings that would not benefit the beneficiary given his other health conditions and treatment intolerance.

The beneficiary, after discussion, elects not to undergo LDCT screening. The physician documents the shared decision-making and the beneficiary's informed decision. The CSDM (G0296) is billed regardless of the screening decision.

Billing: G0296 under ACA waiver — $0.

This case illustrates the value of the CSDM — not all eligible beneficiaries should be screened, and the CSDM is the appropriate venue for individualized discussion.

Worked Example 6: Tobacco Cessation Coordination During Lung Cancer Screening

Beneficiary: 60-year-old man in Cherokee County, current smoker (25 pack-years), undergoing first LDCT screening.

The CSDM at his primary care office at Piedmont includes detailed tobacco cessation counseling. The physician refers him to the Georgia Tobacco Quit Line for coaching and prescribes nicotine replacement therapy (covered under his Part D plan).

LDCT (G0297) at Piedmont. Result: Lung-RADS 2.

Over the next 6 months, the beneficiary completes 4 intensive cessation counseling visits (G0437) with his primary care physician and successfully quits smoking. The Quit Line provides ongoing coaching support.

At his next annual LDCT, he is documented as a former smoker (quit within past 12 months). He remains eligible for screening (quit within past 15 years).

Billing: G0296, G0297, and G0437 cessation counseling all under ACA waiver — $0 to beneficiary. Nicotine replacement therapy covered under Part D with applicable cost-sharing per plan.

Part 12: Best Practices

Best Practice 1: Calculate Pack-Years Accurately

Pack-years are calculated as packs per day multiplied by years of smoking. Accurate calculation requires careful smoking history documentation including changes over time. EHR-integrated calculators support consistent documentation.

Best Practice 2: Perform the CSDM Before Initial Screening

The CSDM is required before initial LDCT screening. Performing the CSDM separately from the LDCT visit allows adequate time for genuine shared decision-making rather than a rushed pre-procedure conversation.

Best Practice 3: Engage in Genuine Shared Decision-Making

The CSDM should be a substantive discussion of benefits and harms, not a rushed sign-off. Patient values, comorbidities, life expectancy, and treatment preferences should inform the discussion.

Best Practice 4: Verify Facility Registry Participation

Medicare-covered LDCT screening requires facility participation in a CMS-designated registry. Verify participation before scheduling. The ACR LCSR facility locator supports verification.

Best Practice 5: Coordinate With Tobacco Cessation

Lung cancer screening is most effective when paired with smoking cessation. The CSDM and annual screening visits provide natural touchpoints for cessation reinforcement.

Best Practice 6: Document Lung-RADS Categories Carefully

Lung-RADS categorization determines management. Careful documentation in the radiology report and clear communication to the referring clinician supports appropriate follow-up.

Best Practice 7: Follow Lung-RADS Management Pathways

Standardized Lung-RADS management pathways reduce variability in care. Following the recommended management for each category supports appropriate balance of timely intervention and minimization of unnecessary workup.

Best Practice 8: Coordinate Multidisciplinary Care for Suspicious Findings

Lung-RADS 4 findings require multidisciplinary evaluation (pulmonology, thoracic surgery, radiology, possibly medical and radiation oncology). Streamlined referral pathways support timely diagnosis and treatment.

Best Practice 9: Counsel on Incidental Findings

LDCT commonly identifies incidental findings (coronary calcifications, thyroid nodules, adrenal abnormalities). Pre-screening counseling addresses expectations; post-screening communication addresses specific findings.

Best Practice 10: Address Cost-Sharing on Diagnostic Follow-Up

Diagnostic follow-up of LDCT findings is subject to standard Part B cost-sharing. Pre-screening counseling addresses this expectation.

Best Practice 11: Engage Rural Beneficiaries Through Regional Coordination

Rural Georgia beneficiaries benefit from coordinated referral pathways from primary care to regional screening centers. Travel coordination and follow-up support improves screening uptake.

Best Practice 12: Support 2022 Expansion Eligibility Awareness

The 2022 expansion approximately doubled the eligible population. Many primary care practices have not fully updated screening referral patterns. Proactive eligibility assessment based on current criteria supports broader screening.

Best Practice 13: Coordinate Cessation Pharmacotherapy

Cessation counseling alone is less effective than counseling combined with pharmacotherapy. Coordinating with Part D plans for cessation pharmacotherapy supports successful quit attempts.

Best Practice 14: Document Adherence Tracking

Annual screening adherence is important for ongoing benefit. EHR-based adherence tracking and patient outreach improve return-for-annual-screening rates.

Part 13: Common Issues

Common Issue 1: Pack-Year Miscalculation

Smoking histories often involve changes over time (rate increases, decreases, periods of cessation). Miscalculation in either direction can produce incorrect eligibility determination.

Common Issue 2: CSDM Skipped or Inadequate

Some referral patterns skip the CSDM or substitute a brief pre-procedure conversation. Inadequate CSDM may produce billing issues and undermines the shared decision-making purpose.

Common Issue 3: Facility Not Registry-Participating

Not all radiology facilities participate in CMS-designated lung cancer screening registries. Beneficiaries scheduled at non-participating facilities may face billing issues.

Common Issue 4: Annual Screening Adherence Drop-Off

Many beneficiaries complete the initial screening but fail to return for annual screening. Adherence drop-off undermines the cumulative benefit of screening.

Common Issue 5: Diagnostic Cost-Sharing Surprise

Beneficiaries with Lung-RADS 3 or 4 findings sometimes are surprised by diagnostic follow-up costs. Pre-screening counseling at the CSDM addresses this.

Common Issue 6: Continued Screening After Age 77

Some beneficiaries continue screening after the age 77 upper limit. Coverage rules limit Medicare-covered screening to age 77.

Common Issue 7: Quit Date Documentation

The "quit within past 15 years" criterion requires accurate quit date documentation. Vague or inconsistent quit date documentation can produce eligibility uncertainty.

Common Issue 8: Symptomatic Patients Routed to Screening

Beneficiaries with symptoms (cough, hemoptysis, weight loss) require diagnostic CT, not screening LDCT. Routing symptomatic patients to screening produces incorrect billing and may miss timely diagnosis.

Common Issue 9: Rural Access Barriers

Rural Georgia counties without local LDCT facilities face access challenges. Coordinating regional referrals supports access but requires intentional effort.

Common Issue 10: 2022 Expansion Underrecognition

Some primary care practices still operate under the 2015 criteria (age 55, 30 pack-years). Updating practice to the 2022 criteria expands screening eligibility appropriately.

Common Issue 11: Cessation Counseling Underutilization

The CSDM requires cessation counseling, and Medicare covers up to 8 cessation counseling visits per year. Beneficiaries who screen but do not pursue cessation miss the most powerful lung cancer mortality reduction intervention.

Common Issue 12: Incidental Findings Workup Variability

Incidental findings on LDCT (thyroid nodules, adrenal masses, coronary calcifications) have variable workup pathways. Some practices over-investigate; others under-investigate. Standardized incidental finding management improves care.

Common Issue 13: Lung-RADS Documentation Gaps

Radiology reports should explicitly document Lung-RADS category. Missing or vague categorization undermines management decisions.

Common Issue 14: Multidisciplinary Coordination Delays

Lung-RADS 4 findings require multidisciplinary evaluation, but coordination between pulmonology, thoracic surgery, and oncology can be delayed. Streamlined pathways and dedicated nurse navigators improve timeliness.

Frequently Asked Questions

1. What is lung cancer screening with low-dose CT?

Lung cancer screening with low-dose CT (LDCT) is an annual chest CT performed at a lower radiation dose than diagnostic CT, designed to detect early-stage lung cancer in eligible high-risk individuals.

2. What law established Medicare coverage for lung cancer screening?

Lung cancer screening was added through National Coverage Determination 210.14 under Section 1861(ddd) preventive services authority, effective February 5, 2015. CMS expanded eligibility effective February 10, 2022.

3. Who is eligible for Medicare-covered LDCT lung cancer screening?

Beneficiaries age 50 to 77, with a 20 pack-year smoking history, who are current smokers or have quit within the past 15 years, are asymptomatic for lung cancer, and have received the required counseling and shared decision-making visit (CSDM) before initial screening.

4. What changed in the 2022 expansion?

CMS lowered the age threshold from 55 to 50 and reduced the pack-year threshold from 30 to 20 pack-years, aligning Medicare coverage with the 2021 USPSTF recommendation update. The expansion approximately doubled the eligible Medicare population.

5. What is a pack-year?

A pack-year is calculated as packs per day multiplied by years of smoking. 1 pack per day for 20 years equals 20 pack-years. 2 packs per day for 10 years also equals 20 pack-years.

6. What is the counseling and shared decision-making visit (CSDM)?

The CSDM (HCPCS G0296) is a required visit before initial LDCT screening that includes eligibility determination, shared decision-making discussion of benefits and harms, adherence counseling, incidental findings counseling, and tobacco cessation counseling.

7. Who can perform the CSDM?

The CSDM must be performed by a physician or qualified non-physician practitioner (nurse practitioner, physician assistant, clinical nurse specialist) within scope of practice.

8. What is the HCPCS code for the LDCT screening?

HCPCS G0297 for LDCT lung cancer screening.

9. How often can I have LDCT screening?

Annually. The frequency reset is typically 11 full months elapsed from the most recent screening.

10. Does Medicare cover the cost of lung cancer screening?

Yes. ACA Section 4104 waives Part B deductible and coinsurance for both the CSDM (G0296) and the LDCT screening (G0297). Beneficiaries pay $0 for the screening services.

11. What if my LDCT finds an abnormality?

Abnormal findings are reported using Lung-RADS categories. Management ranges from continued annual screening (Lung-RADS 1 or 2), to short-interval follow-up (Lung-RADS 3 or 4A), to biopsy or other diagnostic workup (Lung-RADS 4B or 4X).

12. Is the diagnostic workup of abnormal findings covered?

Yes, but with standard Part B cost-sharing rather than the ACA Section 4104 waiver. Follow-up CT, PET-CT, biopsy, and specialist consultation are subject to Part B deductible plus 20% coinsurance.

13. What is Lung-RADS?

Lung-RADS (Lung Imaging Reporting and Data System) is the standardized reporting system for LDCT findings developed by the American College of Radiology. It categorizes findings from 1 (negative) through 4X (highly suspicious for malignancy) and specifies management pathways for each category.

14. What is the radiation exposure of LDCT?

LDCT typically delivers an effective radiation dose of less than 1.5 millisieverts (mSv) per scan, compared to approximately 7-8 mSv for standard diagnostic chest CT and approximately 0.05 mSv for a chest X-ray.

15. Must the radiology facility be certified or registered?

Yes. Medicare-covered LDCT facilities must participate in a CMS-designated lung cancer screening registry (typically the American College of Radiology Lung Cancer Screening Registry).

16. Can my primary care physician perform the CSDM?

Yes. Primary care physicians, nurse practitioners, physician assistants, and clinical nurse specialists can perform the CSDM within their scope of practice.

17. Does Medicare cover tobacco cessation counseling?

Yes. Medicare covers tobacco cessation counseling under HCPCS G0436 (intermediate counseling) and G0437 (intensive counseling) regardless of symptoms. Up to 8 cessation counseling visits per year are covered. The ACA Section 4104 waiver applies — beneficiaries pay $0.

18. Does Medicare cover smoking cessation pharmacotherapy?

Medicare Part D plans typically cover cessation pharmacotherapy including nicotine replacement therapy, varenicline (Chantix), and bupropion sustained-release (Zyban). Coverage details and cost-sharing vary by plan.

19. What is the Georgia Tobacco Quit Line?

The Georgia Tobacco Quit Line (1-877-270-7867) provides free cessation counseling and resources to Georgia residents including coaching support and cessation planning.

20. What if I quit smoking more than 15 years ago?

Beneficiaries who quit smoking more than 15 years ago are not eligible for Medicare-covered LDCT screening. The 15-year limit reflects the diminishing residual lung cancer risk over time after cessation.

21. What if I am older than 77?

Medicare-covered LDCT screening is limited to beneficiaries age 50 to 77. Beneficiaries older than 77 are not eligible for Medicare-covered screening, reflecting the diminishing benefit-harm balance in older populations.

22. Does Medicare Advantage cover lung cancer screening?

Yes. Medicare Advantage plans must cover at least the same benefits as Original Medicare, including LDCT screening for eligible beneficiaries.

23. How do I find a lung cancer screening facility in Georgia?

You can use the American College of Radiology Lung Cancer Screening Registry facility locator, contact your primary care physician for a referral, or contact major Georgia lung cancer screening programs directly: Emory Lung Cancer Screening Program, Wellstar Lung Cancer Screening, Piedmont Lung Cancer Screening, Northside Hospital, and Augusta University Lung Cancer Screening.

24. What if I have COPD or other lung disease?

Beneficiaries with COPD or other lung disease may still be eligible for LDCT screening if they meet the eligibility criteria. Existing lung disease does not disqualify, but the CSDM should address how lung disease affects shared decision-making (treatment tolerance for any cancer that might be diagnosed).

25. What is the Annual Wellness Visit role in lung cancer screening?

The AWV is the natural coordinating visit for lung cancer screening discussions including smoking history documentation, eligibility assessment, CSDM scheduling, and annual screening adherence support.

26. Where can I get help understanding my lung cancer screening coverage in Georgia?

Contact GeorgiaCares SHIP (1-866-552-4464) for free, unbiased Medicare counseling. You can also contact Medicare directly at 1-800-MEDICARE, the Medicare Rights Center at 1-800-333-4114, the American Lung Association at 1-800-586-4872, or LUNGevity Foundation at 1-844-360-5864.

Contacts and Resources

1. Medicare — 1-800-MEDICARE (1-800-633-4227) for general Medicare questions and coverage.
2. Palmetto GBA Medicare Administrative Contractor — 1-866-238-9650 for Medicare claims and coverage in Georgia.
3. Georgia Department of Community Health Member Services — 1-866-211-0950 for Georgia Medicaid coordination.
4. GeorgiaCares SHIP — 1-866-552-4464 for free Medicare counseling.
5. Medicare Rights Center — 1-800-333-4114 for Medicare advocacy and assistance.
6. Atlanta Legal Aid — 404-377-0701 for legal assistance with Medicare issues.
7. Georgia Legal Services Program — 1-800-498-9469 for legal assistance outside metropolitan Atlanta.
8. 211 Georgia — Dial 211 for community resource referrals.
9. Eldercare Locator — 1-800-677-1116 for connection to local aging services.
10. Georgia Department of Public Health — 404-657-2700 for state public health resources.
11. American Cancer Society — 1-800-227-2345 for cancer information, support, and resources.
12. American Lung Association — 1-800-586-4872 for lung health information and support.
13. LUNGevity Foundation — 1-844-360-5864 for lung cancer-specific information and patient support.
14. Georgia Tobacco Quit Line — 1-877-270-7867 for free cessation counseling and resources.
15. American College of Radiology — 1-800-227-5463 for ACR Lung Cancer Screening Registry facility verification.
16. Emory Lung Cancer Screening Program — Academic LDCT screening in Atlanta.
17. Wellstar Lung Cancer Screening — Network LDCT screening in north and west Georgia.
18. Acentra Health QIO — 1-844-455-8708 for Medicare quality of care concerns.